Shattuck Labs, Inc. (STTK) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Austin, TX, アメリカ. 現CEOは Taylor H. Schreiber.
STTK を有する IPO日 2020-10-09, 44 名の正社員, に上場 NASDAQ Global Select, 時価総額 $324.78M.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
